NASDAQ:APGE 22 June 2026

AbbVie beats analyst estimates and posts one-day value jump bigger than Apogee deal size

AbbVie Inc. jumped about $17.8 billion in market cap Thursday, outpacing the value of the deal that’s driving a fresh look at the drugmaker from investors. Shares closed up 3.99% at $261.07 after hitting a 52-week high of $261.64, with the move coming off a $10.01 gain on roughly 1.77 billion shares outstanding.

3 July 2026

Earnings Reports·NASDAQ:APGE·NYSE:ABBV·Stock Market

AbbVie stock run lifts pricing on $10.9 billion Apogee deal to six times cost

U.S. cash equities didn’t trade Sunday, so AbbVie’s most recent close is Friday at $253.35. That’s a 4.2% gain for the day and up 17.0% since June 18, which was the last session ahead of the Juneteenth break and before AbbVie’s deal week kicked off.

29 June 2026

NASDAQ:APGE·NYSE:ABBV·Pharmaceutical Industry·Stock Market

AbbVie grabs Apogee in $10.9 billion deal as buyouts speed up

AbbVie (NYSE:ABBV) jumps $18 billion Friday, beats Apogee as Skyrizi FDA decision comes Monday

U.S. equity markets were closed for the weekend, so the main takeaway on AbbVie Inc. last week wasn’t limited to the Apogee deal. Investors saw fresh market value assigned to that deal as shares swung again Friday.

27 June 2026

NASDAQ:APGE·NYSE:ABBV·Stock Market

Alphabet rout dents Nasdaq, oil slide gives Dow a lift

Alphabet weighed on U.S. stocks Monday, sending indexes in different directions. The S&P 500 slipped 0.48% to 7,464.36 and the Nasdaq Composite fell 1.41% to 26,143.95. The Dow Jones Industrial Average managed a 0.12% gain to 51,628.79, according to LSEG data on Reuters.

22 June 2026

Nasdaq·NASDAQ:AMZN·NASDAQ:APGE·NASDAQ:GOOGL·NASDAQ:META·NASDAQ:MSFT·NASDAQ:MU·NASDAQ:SPCX·NYSE:ABBV·Oil Prices·Stock Market

AbbVie grabs Apogee in $10.9 billion deal as buyouts speed up

AbbVie said Monday it will buy Apogee Therapeutics for $10.9 billion in cash, picking up a late-stage eczema drug in what would be its biggest deal in over five years. The $135.11 per share offer is about 49% over Apogee’s June 18 close. Both companies’ boards signed off, aiming to wrap up the deal in the third quarter.

22 June 2026

NASDAQ:APGE·NYSE:ABBV·Pharmaceuticals·Stock Market

Apogee Therapeutics (NASDAQ:APGE) stock jumps on AbbVie’s $10.9 billion cash takeover

Apogee Therapeutics shares surged on Monday after AbbVie agreed to acquire the biotech company for $10.9 billion in cash, giving the U.S. drugmaker control of a long-acting immunology drug candidate aimed at eczema and asthma. Apogee was recently trading at $132.69, up about 47%, against AbbVie’s $135.11-a-share offer.

22 June 2026

NASDAQ:APGE·NYSE:ABBV·Pharmaceutical Industry·Stock Market

NASDAQ:APGE 22 June 2026 - 3 July 2026

AbbVie beats analyst estimates and posts one-day value jump bigger than Apogee deal size

AbbVie stock run lifts pricing on $10.9 billion Apogee deal to six times cost

AbbVie (NYSE:ABBV) jumps $18 billion Friday, beats Apogee as Skyrizi FDA decision comes Monday

Alphabet rout dents Nasdaq, oil slide gives Dow a lift

AbbVie grabs Apogee in $10.9 billion deal as buyouts speed up

Apogee Therapeutics (NASDAQ:APGE) stock jumps on AbbVie’s $10.9 billion cash takeover